A new partnership for Houston-based Syzygy will generate 1.2 million tons of clean hydrogen each year in South Korea by 2030. Image via Syzygy

Houston-area energy tech startup Syzygy Plasmonics is part of a new partnership that will develop a fully electric chemical reactor for production of clean hydrogen in South Korea.

The reactor will be installed in the second half of 2023 at Lotte Fine Chemical’s facilities in Ulsan, South Korea. Lotte Fine Chemical, Lotte Chemical, and Sumitomo Corporation of Americas are Syzygy’s partners in this venture.

The Lotte Fine Chemical installation marks the first time Syzygy’s technology will be used in a commercial setting.

Using green ammonia, Lotte Fine Chemical plans to generate 1.2 million tons of clean hydrogen each year in South Korea by 2030.

The traditional thermal cracking of ammonia uses high heat and pressure to convert it to hydrogen gas. The heat required to drive this process is achieved by burning fossil fuels, meaning ammonia cracking is quite carbon-intensive. Using fully electric reactors gives hydrogen producers a way to reduce or eliminate reliance on combustion to process ammonia.

Syzygy has developed reactor technology that uses light from ultra-high-efficiency LEDs to power chemical reactions, eliminating the traditional method of producing hydrogen with heat from burning fuel.

“Simply improving existing tech isn’t enough to reach the world’s decarbonization goals. Stopping climate change will require industries to reimagine what is possible,” Syzygy co-founder and CEO Trevor Best says in a news release. “Our technology expands the accepted paradigms of chemical engineering. We have demonstrated the ability to replace heat from combustion with renewable electricity in the manufacture of foundational chemicals like hydrogen.”

Sumitomo, a Japanese conglomerate with a Houston office, first invested in Syzygy in 2019. Sumitomo executive Shinichi Hasegawa says the partnership with Syzygy and Lotte “is one of the important steps we are taking to make good on our commitment to achieve carbon neutrality by 2050, and lead the decarbonization of society.”

Lotte Chemical produces raw materials for a variety of chemical products, including ethylene. Lotte Fine Chemical makes an array of chemical products. Both companies are based in Seoul, South Korea.

In May, Syzygy announced it was moving its headquarters from 9000 Kirby Dr. in Houston to Pearland. It’s leasing a 44,800-square-foot building in Pearland for its headquarters, R&D operations, and manufacturing facilities. The facility, expected to open later this year at 3250 S. Sam Houston Pkwy., will be home to about 60 employees.

Founded in 2017, Syzygy has created technology that produces clean hydrogen from various feedstocks. Syzygy’s technology is based on a field of science called photocatalysis, which uses light from LEDs driven by renewable electricity to perform chemical reactions. The technology can electrify the production of chemicals such as hydrogen, liquid fuels, and fertilizer.

In 2021, the startup — whose technology is based on Rice University research and was recently recognized as a most-promising company by investors — raised $23 million in series B funding. According to Crunchbase, Syzygy has raised a total of $30 million.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”